COVID-19 Update

Better coordination in development and review of vaccines is needed.

Advances in technology are accelerating the development and manufacture of subunit vaccines.

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

October 26, 2021

Moderna’s KidCOVE study showed a robust neutralizing antibody response in children aged six to under 12.

October 22, 2021

Pfizer and BioNTech’s Phase III trial demonstrated 95.6% booster efficacy relative to participants who received placebo.

October 22, 2021

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

October 22, 2021

EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.

October 22, 2021

UK government has secured two new antiviral treatments for COVID-19, which may be rolled out in a national clinical study before the end of 2021.

October 21, 2021

In addition to allowing booster shots of the Moderna and J&J vaccines, FDA approved heterologous booster shots.

October 15, 2021

The council voted 19–0 to recommend that FDA authorize booster doses of the Moderna COVID-19 vaccine for certain populations.

October 14, 2021

Roche has submitted a marketing authorization application to EMA for Ronapreve (casirivimab/imdevimab) as a treatment for COVID-19.

October 14, 2021

EMA has halted the rolling review of CureVac's COVID-19 candidate, CVnCoV, due to the company withdrawing from the process.

October 12, 2021

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.